RxDoctor Payments Data

Vasty Kum

Psychiatric/Mental Health · Union, NJNPI 1750055703

Payments from drug & device makers

$4,135in general payments, 2019–2025

Across 220 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$697
  • Johnson & Johnson$545
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
  • Neurocrine Biosciences, Inc.$240
  • E.r. Squibb & Sons, L.L.C.$216
  • plus $653 from 8 others

What the payments were for

  • Food & beverage$4,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,135 in reported general payments places this provider in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$35,309
Medicare patients
83
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole26$38,896
VraylarCariprazine Hcl25$35,003
Aripiprazole151$6,494
Clozapine44$3,466
Bupropion XlBupropion Hcl114$2,439
Ziprasidone Hcl16$2,212
Paliperidone ErPaliperidone22$2,123
Quetiapine Fumarate151$1,957
Lamotrigine251$1,657
Vilazodone Hcl12$1,584
Olanzapine32$1,434
Duloxetine Hcl131$1,343
Bupropion Hcl SrBupropion Hcl99$1,205
Venlafaxine Hcl ErVenlafaxine Hcl94$1,166
Buspirone Hcl76$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$697$38,89626 claims
AbbVieVraylar$1,397$35,00325 claims
Almatica Pharma LLCSertraline Hcl$15$773109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →